sulfonylureas, metformin, thiazolidinediones, glitinides, alphaglucosidase
inhibitors or insulin use prior to study enrollment;
participation in another clinical trial within 30 days of screening;
long-term diabetic complications such as diabetic retinopathy,
diabetic neuropathy which need therapy (painful peripheral neuropathy,
systemic orthostatic hypotension, urinary retention, foot
ulcers or gastric stasis); a body mass index (BMI) less than 18 or
greater than 38; or a body weight variation more than 10% during
the screening period.